Members of the Edgewise team are headed to Prague for #WMS2024! Join neuromuscular experts, Luca Bello and Craig McDonald, for our scientific symposium “Understanding disease progression and a potential novel agent to protect muscle,” taking place on Oct 8 at 4:30pm CEST, and check out our seven poster presentations! Learn more here: https://lnkd.in/eAVEDyHD. Don’t forget to stop by booth #21 and say hello to our team: Kevin, Alan, Joanne, Behrad, Roxana, John, Nicholas, Abby, Lindsay Nelson, and Emily. See you in Prague!
Edgewise Therapeutics
Biotechnology Research
Boulder, CO 10,854 followers
On a mission to improve the lives of people facing serious muscle disease.
About us
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions.
- Website
-
https://edgewisetx.com/
External link for Edgewise Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boulder, CO
- Type
- Public Company
- Founded
- 2017
Locations
-
Primary
1715 38th St.
Boulder, CO 80301, US
Employees at Edgewise Therapeutics
-
Mike Carruthers
CFO Edgewise Therapeutics
-
Bruce D. Johnson
Pharmaceutical R&D Scientific Expertise Balanced with Business Acumen | Concept-to-Launch CMC Product Development | Collaborative Leader
-
Chris Dufton, PhD
Clinical Development and Operations Expert with 25 years of Clinical Research Experience
-
Behrad Derakhshan, PhD
Chief Business Officer at Edgewise Therapeutics
Updates
-
We’re headed to Atlanta, Georgia for Muscular Dystrophy Association Engage to connect with the patient community! Abby Bronson will be participating in the Drug Development Roundtable taking place on Oct 5th. To learn more about the symposium, or to register, visit: https://lnkd.in/e-ivaF8S. See you there! #BeckerMD #BeckerDiseaseAwarenessWeek #MuscularDystrophy #Duchenne
-
Joanne Donovan, M.D., Chief Medical Officer at Edgewise Therapeutics, was recently interviewed by Know Rare about our clinical development program in Becker muscular dystrophy. Listen to the full interview here: https://lnkd.in/ggxKiXws
The latest episode of Rare Insights is LIVE! 🎙️ Tune in as host Taren Grom sits down with Dr. Joanne Donovan, Chief Medical Officer at Edgewise Therapeutics, to explore cutting-edge treatments for rare neuromuscular and cardiac diseases like Becker and Duchenne muscular dystrophy. In Episode 4: “Conquering the Science of Muscle Disease with Edgewise Therapeutics”, we cover: • Edgewise’s innovative “muscle as an organ” approach. • The unique mechanism behind EDG-5506, targeting muscular dystrophy. • Challenges and breakthroughs in drug development for Duchenne and Becker patients. • How Edgewise incorporates the patient voice in every step of development. What’s on the horizon for muscle disease research. 🎧 Search ‘Rare Insights’ in your favorite podcast player and stream episode 4 now! Learn more: https://lnkd.in/ggxKiXws - #RareInsightsPodcast #raredisease #rarediseases #rarediseaseawareness #beckermusculardystrophy #musculardystrophy #becker #Duchennemusculardystrophy #EdgewiseTherapeutics #KnowRare Edgewise Therapeutics
-
Obtenga más información sobre un estudio clínico diseñado para adultos diagnosticados con distrofia muscular de Becker. Acceda a un estudio sobre Becker: beckergcstudy.com/es. -- -- -- GRAND CANYON, a pivotal clinical study to evaluate an investigational drug in individuals living with #Becker #MuscularDystrophy, is ongoing. Visit the study website to learn more: beckergcstudy.com/.
-
Have a heart-to-heart about your family’s heart history! HCM symptoms can appear at any age. Talk to your doctor about the signs and how to detect an early diagnosis. To learn more about HCM, visit: https://lnkd.in/dnrtt353 #HCM #HCMAwareness #EdgewiseTherapeutics
-
For many people affected by Becker muscular dystrophy, meeting and talking with others experiencing similar challenges and triumphs can improve quality of life and help combat feelings of isolation. We're so excited for the Becker Education and Engagement Day this weekend. To connect with the growing Becker community, check out Becker Education and Engagement Day on Sept 28. Follow the link to register: https://lnkd.in/gzCrhYA4. #Becker #BeckerMD #MuscularDystrophy
-
We’re attending the 2024 Heart Failure Society of America’s Annual Scientific Meeting in Atlanta, GA! Join Chris Dufton, PhD, Marc Semigran, Marc Evanchik, Aylin Tugcu and, and Laura Emery for our two poster presentations on the CIRRUS-HCM study on Sept 28 at 7:45am ET and EDG-7500 Healthy Volunteer data on Sept 29 at 1:15pm ET. See you there!
-
Today we announced positive top-line data from the Phase 1 trial in healthy subjects and Phase 2 CIRRUS-HCM trial in patients with obstructive hypertrophic cardiomyopathy. See our press release to learn more: https://lnkd.in/gw9Dpkzg
-
Contribute to the future of others like yourself. Access a study in Becker. Learn more beckergcstudy.com.
-
We’re looking for passionate individuals to join our team! If you’re eager to impact the lives of those with rare muscle disorders, we’d love to meet you. Tap the link to explore career openings and learn more about a career at Edgewise: https://lnkd.in/eG_pgJbU #EdgewiseTherapeutics